Have a feature idea you'd love to see implemented?
Let us know!
ALDX Aldeyra Therapeutics Inc
Price (delayed)
$5.23
Market cap
$310.77M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.64
Enterprise value
$255.38M
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's
Highlights
Aldeyra Therapeutics's debt has decreased by 3.2% YoY
The company's EPS rose by 28% YoY but it fell by 25% QoQ
The net income has grown by 27% YoY but it has contracted by 26% from the previous quarter
The quick ratio has dropped by 55% year-on-year and by 29% since the previous quarter
ALDX's equity is down by 24% year-on-year and by 13% since the previous quarter
Key stats
What are the main financial stats of ALDX
Market
Valuations
Earnings
Shares outstanding
59.42M
Market cap
$310.77M
Enterprise value
$255.38M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.16
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$35.84M
EBITDA
-$35.59M
Free cash flow
-$30.72M
Per share
Balance sheet
Liquidity
EPS
-$0.64
Free cash flow per share
-$0.52
Book value per share
$1.65
Revenue per share
$0
TBVPS
$2.12
Total assets
$126.04M
Total liabilities
$27.73M
Debt
$15.64M
Equity
$98.31M
Working capital
$98.05M
Debt to equity
0.16
Current ratio
4.55
Quick ratio
4.36
Net debt/EBITDA
1.56
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-26.9%
Return on equity
-33.3%
Return on invested capital
-195.7%
Return on capital employed
-36.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ALDX stock price
How has the Aldeyra Therapeutics stock price performed over time
Intraday
-1.32%
1 week
-2.61%
1 month
-9.67%
1 year
-10.75%
YTD
49%
QTD
-2.97%
Financial performance
How have Aldeyra Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$43.05M
Net income
-$37.87M
Gross margin
N/A
Net margin
N/A
The net income has grown by 27% YoY but it has contracted by 26% from the previous quarter
Aldeyra Therapeutics's operating income has increased by 23% YoY but it has decreased by 22% QoQ
Growth
What is Aldeyra Therapeutics's growth rate over time
Valuation
What is Aldeyra Therapeutics stock price valuation
P/E
N/A
P/B
3.16
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 28% YoY but it fell by 25% QoQ
ALDX's price to book (P/B) is 44% more than its last 4 quarters average of 2.2 and 17% more than its 5-year quarterly average of 2.7
ALDX's equity is down by 24% year-on-year and by 13% since the previous quarter
Efficiency
How efficient is Aldeyra Therapeutics business performance
The return on invested capital rose by 39% since the previous quarter and by 4.3% year-on-year
The ROE has contracted by 35% from the previous quarter but it has grown by 7% YoY
The return on assets has declined by 33% since the previous quarter but it has increased by 10% year-on-year
Dividends
What is ALDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ALDX.
Financial health
How did Aldeyra Therapeutics financials performed over time
The quick ratio has dropped by 55% year-on-year and by 29% since the previous quarter
The current ratio has dropped by 54% year-on-year and by 30% since the previous quarter
Aldeyra Therapeutics's debt is 84% lower than its equity
The company's debt to equity rose by 33% YoY and by 14% QoQ
ALDX's equity is down by 24% year-on-year and by 13% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.